
First Patient Dosed With Azenosertib in Cyclin E1+ Ovarian Cancer
The first patient with Cyclin E1-positive platinum-resistant ovarian cancer has been dosed with azenosertib in part 2a of the phase 2 registration-intent, DENALI clinical trial, according to a news release from Zentalis Pharmaceuticals, Inc. The …